Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Evaluation Video

Oral Presentation

Session: Vaccine Safety Across Ages & Platforms

Evaluation of Febrile Seizure Risk Following Ancestral Monovalent COVID-19 mRNA Vaccination Among U.S. Children Aged 2-5 Years

Monday, August 26, 2024
2:15 PM – 2:30 PM CEST
Location: Conv Hall I C
Background: The U.S. Food and Drug Administration’s Biologics Effectiveness and Safety (BEST) Initiative detected a statistical signal for seizures/convulsions following exposure to BNT162b2 in individuals aged 2-4 years and mRNA-1273 in individuals aged 2-5 years. The crude association from initial safety monitoring does not imply causality; further evaluations were performed to assess post-vaccination risk of seizures.

Objectives: To evaluate febrile seizure risk following monovalent COVID-19 vaccination among children aged 2-5 years.

Methods: A self-controlled case series analysis was performed to compare the risk of febrile seizure in the risk interval following vaccination (0-1 days) to a control interval (8-63 days). The primary analysis included individuals aged 2-5 vaccinated with mRNA-1273 and individuals aged 2-4 vaccinated with BNT126b2 who had a febrile seizure outcome following COVID-19 vaccination from three commercial insurance databases (Optum, Carelon Research, CVS Health). Exposure was defined as receipt of dose 1 and/or dose 2 of COVID-19 ancestral monovalent mRNA vaccines. A conditional Poisson regression model was used to compare outcome rates in risk and control intervals and estimate incidence rate ratios (IRR) and 95% confidence intervals (CIs) in each database. From the conditional Poisson regression model, we derived the attributable risk (AR) per 100,000 vaccinations. Meta-analyses were used to pool results across databases.

Results: There were 10 febrile seizures observed in the risk window following 110,126 mRNA-1273 doses and 7 febrile seizures observed in the risk window following 163,733 BNT162b2 doses. The primary meta-analysis found a statistically significant increased incidence of febrile seizure in the 0-1 days following mRNA-1273 vaccination compared to the control interval (IRR: 2.52, 95% CI: 1.35 to 4.69). For the BNT162b2 vaccination, the IRR was elevated but not statistically significant (IRR: 1.41, 95%CI: 0.48 to 4.11). We estimated an AR of 3.22 excess febrile seizure events per 100,000 mRNA-1273 vaccinations (95%CI -0.31 to 6.75), and no excess febrile seizure events following BNT162b2 vaccination (AR: 0.25 per 100,000 vaccinations 95%CI -2.75 to 2.24).

Conclusions: Among children aged 2-5 years who experienced febrile seizures following vaccination, the analysis showed an elevated IRR of febrile seizures in the 0-1 days following the mRNA-1273 vaccination; however, absolute risk was low. Based on the current body of scientific evidence, the safety profile of the ancestral monovalent COVID-19 mRNA vaccines remains favorable for use in young children.